Follows adults with moderate to severe COPD using Breztri/Trixeo in routine care
Observes how adults with lung disease COPD fare on Breztri/Trixeo in everyday care.
Key facts
- Who runs it
- AstraZeneca
- Where
- Dubai, United Arab EmiratesSee the siteAlso in 11 other countries, 31 sites
- Trial code
- Registry title
- Study of Clinical and Patient-reported Outcomes in Adults With Moderate to Severe COPD Treated With Breztri/Trixeo
- Status
- Recruiting
- People taking part
- 1,400 people, planned
- Started
- 15 Dec 2025
- Expected to end
- 31 Dec 2027
- Type of study
- Observational
- Record updated
- 10 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with COPD who have been prescribed Breztri/Trixeo (BGF) but have not started it yet. Doctors follow them for 12 months in routine care.
- Age
- Over 30 and under 80 years old.
- Sex
- Men and women can join.
- Disease stage
- COPD diagnosed at least 12 months before the start of the study. The title says moderate to severe COPD.
- Earlier treatment
- Must have been prescribed BGF but not yet started it. Cannot join if treated with a triple fixed-dose combination therapy in the 12 months before screening, or with Multiple Inhaled Triple Therapy (MITT) in the last 3 months.
Main reasons for not taking part
- COPD due to documented α-1 antitrypsin deficiency
- Major heart or lung event needing hospital care in the last 3 months or less
- Hospitalised for a COPD flare-up in the 30 days before enrolment
- Pregnant, planning pregnancy, or breastfeeding
- Current asthma, tuberculosis, lung cancer, or other active lung disease
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- The study will include patients who were prescribed BGF, but not yet initiated, according to the label (SmPC) and local market reimbursement criteria. Patients will only be included in the study if they meet the following inclusion criteria:
- Patients diagnosed with COPD, at least 12 months before baseline, as assessed per physician's routine practice or as documented in the patient's chart
- Male or female patients aged over 30 years and under 80 years at the time of enrolment
- Patients providing a written Informed Consent* prior to inclusion to the study; *Prescription of BGF should be prior to the signed informed consent and the decision to prescribe this therapy is clearly separated from the physician's decision to include the patient in the current study
- Patients able and willing to read and to comprehend written instructions, and to comprehend and complete the questionnaires required by the protocol
Who cannot take part
- Patients previously treated with triple fixed-dose combination therapies 12 months before the screening visit or treated with Multiple Inhaled Triple Therapy (MITT) within the last 3 months before the screening visit
- Patients hospitalized due to COPD exacerbations within the last 30 days prior to enrolment
- Patients currently participating in a non-interventional observational trial that might, in the investigator's opinion, influence the assessment for the current study or participation in any interventional trial in the last 30 days prior to enrolment
- Patients with respiratory tract infection (including COVID-19 infection) ) that has not resolved ≤30 days prior to BGF MDI initiation and those exhibiting persistent long-COVID symptoms are excluded from the study
- Patients with recent (≤3 months) major cardiac or pulmonary events that required hospitalization (e.g., myocardial infarction, pulmonary embolism)
- Patients with a current diagnosis of asthma, active tuberculosis, lung cancer or lung metastasis, significant bronchiectasis, sarcoidosis, pulmonary fibrosis, pulmonary hypertension, interstitial lung diseases, or other active clinically significant pulmonary diseases
- Patients who meet any of the following criteria will not be eligible to participate in the study:
- Patients with COPD due to documented α-1 antitrypsin deficiency
- Currently pregnant (or intending to become pregnant), breastfeeding, or lactating women
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 30 and 80 years old?
Where in United Arab Emirates
Also in 11 other countries, 31 sites
- DubaiHospital not named in the registryTaking people
About the trial
What the trial wants to find out
Chronic Obstructive Pulmonary Disease is a leading cause of global morbidity and mortality, especially in low- and middle-income countries. Exacerbations accelerate disease progression and increase the risk of death. Recent recommendations from the GOLD report emphasize the diagnosis of COPD and treatment planning based on a combination of lung function metrics, exacerbation history, and patient-reported symptoms. It is recommending the use of triple combination therapy (ICS+LABA+LAMA) such as BREZTRI/TRIXEO as one of the options in Group E patients. While BGF has demonstrated efficacy in controlled clinical trials, real-world evidence is needed to assess its impact on daily patient outcomes and quality of life.
Read full original descriptionShow less
The iCHOROS study is a real-world, international, multicenter, observational study aiming to evaluate changes in clinical and patient-reported outcomes in adults with moderate to severe COPD treated with BGF for 12 months in routine care settings across Latin America, Asia, and the Middle East \& Africa. The study will provide valuable insights into the effectiveness and patient experience of BGF therapy in diverse, real-world populations
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Real-world, International, Multicentre, Non-interventional, Prospective Cohort to Assess Clinical and Patient-reported Outcomes in Adults With Moderate to Severe COPD Treated With Breztri/Trixeo in Routine Care Settings
- Plain-language title
- Follows adults with moderate to severe COPD using Breztri/Trixeo in routine careGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 11 November 2026.
- Fit questions
- Built from NCT07069829, who can take part
- Record updated
- 10 November 2026